Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label Long-Term Safety Study of BHV3000 in the Acute Treatment of Migraine

Trial Profile

A Multicenter, Open Label Long-Term Safety Study of BHV3000 in the Acute Treatment of Migraine

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Sponsors Biohaven Pharmaceutical; Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 22 Jan 2019 Status changed from active, no longer recruiting to recruiting.
    • 10 Dec 2018 Results (database cutoff of November 21, 2018) presented in the Biohaven Pharmaceutical media release.
    • 31 Oct 2018 Planned End Date changed from 1 Oct 2019 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top